Chapin Davis Inc. Increases Stock Position in Dyadic International Inc. $DYAI

Chapin Davis Inc. grew its position in shares of Dyadic International Inc. (NASDAQ:DYAI) by 4.7% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 882,849 shares of the biotechnology company’s stock after buying an additional 40,000 shares during the quarter. Chapin Davis Inc.’s holdings in Dyadic International were worth $874,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in DYAI. Callan Capital LLC raised its position in Dyadic International by 86.8% in the first quarter. Callan Capital LLC now owns 50,759 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 23,585 shares during the period. Bank of America Corp DE lifted its position in shares of Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 26,965 shares in the last quarter. Jane Street Group LLC purchased a new stake in Dyadic International during the 4th quarter worth about $45,000. Finally, Millennium Management LLC bought a new position in shares of Dyadic International in the fourth quarter valued at approximately $28,000. 27.95% of the stock is currently owned by institutional investors.

Dyadic International Stock Performance

Shares of DYAI opened at $1.07 on Monday. The company has a debt-to-equity ratio of 5.40, a current ratio of 2.02 and a quick ratio of 2.02. The firm has a market capitalization of $38.72 million, a PE ratio of -5.63 and a beta of 0.95. The company has a 50-day simple moving average of $0.95 and a two-hundred day simple moving average of $1.07. Dyadic International Inc. has a one year low of $0.71 and a one year high of $2.20.

Dyadic International (NASDAQ:DYAI) last announced its earnings results on Wednesday, August 13th. The biotechnology company reported ($0.06) EPS for the quarter, meeting analysts’ consensus estimates of ($0.06). Dyadic International had a negative net margin of 134.84% and a negative return on equity of 355.39%. The firm had revenue of $0.97 million for the quarter, compared to analysts’ expectations of $0.60 million. On average, analysts anticipate that Dyadic International Inc. will post -0.18 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum started coverage on Dyadic International in a research note on Monday, September 8th. They set a “buy” rating for the company. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $6.00.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.